A Phase 2 interventional study of Capecitabine and Ruxolitinib in Pancreatic Cancer, sponsored by Incyte Corporation. Completed at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-12.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pancreatic Neoplasms by Incyte Corporation — 1 open to participants now, 2 under way, 1 of them phase 3. Pancreatic Neoplasms · Incyte Corporation.
Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 2 in phase 2, and was the 1st registered.
3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →1 of the 10 studies in Pancreatic Neoplasms by Incyte Corporation is open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Australia, Austria and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 3
First in 2011; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 111 across the 10 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Pancreatic Neoplasms by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
The study consisted of an open-label, safety run-in period that was composed of 1 patient cohort with 9 patients/cohort. This phase of the study determined the safety of the capecitabine/ruxolitinib combination in this patient population.
A randomized, double-blind study with two treatment arms was conducted once the safety run-in results from the first part of the study showed that the capecitabine/ruxolitinib combination was safe and additional patients could be treated. All patients have received capecitabine therapy in addition to the ruxolitinib or placebo (Study Drug).
Treatment for all patients consisted of repeating 21-day cycles. Capecitabine was self-administered for the first 14 days of each cycle, and the Study Drug was self-administered during the entire 21-day cycle. Treatment cycles continued as long as the regimen was tolerated and the patient did not meet any of the discontinuation criteria. In the event of disease progression, capecitabine therapy was discontinued but the Study Drug could continue to be administered. Subjects who discontinued treatment with the Study Drug continued to be followed to obtain information regarding subsequent treatment regimens and survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have failed gemcitabine treatment for metastatic pancreatic cancer:
o An alternate chemotherapeutic agent was an acceptable substitute as 1st-line therapy in the event that the subject was intolerant to or ineligible to receive gemcitabine
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Capecitabine · Drug: Ruxolitinib
Drug: Capecitabine · Drug: Placebo
Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
Placebo matching ruxolitinib
Overall Survival
Overall survival was measured as the length of time (in days) between the randomization date and the date of death.
Time frame: Primary analysis includes study data from the start of the study (first dose for that subject) until the death of the subject (up to 8 months).
Progression-Free Survival (PFS)
Progression-free survival was defined as the length of time between the date of randomization and the earlier of death or progressive disease (PD), whichever was earlier, as assessed by RECIST. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: Analysis includes study data from the start of the study (first dose for that subject) until death or PD, whichever was earlier up to 8 months.
Objective Response Rate
Objective response rate (ORR) was defined as the percentage of participants with either a confirmed complete response (CR) or partial response (PR) measured by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria during the treatment period. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Measured every 4 weeks for duration of study treatment (up to 8 months)
Durable Response Rate
Durable response was defined as subjects with a response of Partial response (PR) or better at 2 subsequent measurements that were at least 4 weeks apart.
Time frame: Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months)
Summary of Clinical Benefit
A subject was considered a clinical benefit responder if he/she met at least 1 of the following criteria: 1. Subject showed improvement in at least one of the following parameters on successive scheduled observations without worsening in the others: pain intensity, analgesic use, or performance status 2. Subject was stable or improved on the pain intensity, analgesic use, and performance status and had a ≥ 7% increase in body weight maintained for 2 consecutive reporting periods that was not because of fluid accumulation.
Time frame: Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months)
The open-label, safety run-in (1 cohort) was designed to confirm the safety of the combination of ruxolitinib and capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas. The double-blind portion was 2 treatment groups randomized 1:1: ruxolitinib plus capecitabine or matching placebo plus capecitabine.
| Milestone | Ruxolitinib | Placebo |
|---|---|---|
| Started | 9 | 0 |
| Completed | 0 | 0 |
| Not completed | 9 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Disease progression | 3 | 0 |
| Withdrew: Patient decision | 1 | 0 |
| Milestone | Ruxolitinib | Placebo |
|---|---|---|
| Started | 64 | 63 |
| Completed | 1 | 0 |
| Not completed | 63 | 63 |
| Withdrew: Adverse event | 4 | 10 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Physician decision | 16 | 13 |
| Withdrew: Other - unspecified | 37 | 31 |
| Withdrew: Patient decision | 5 | 9 |
Overall survival was measured as the length of time (in days) between the randomization date and the date of death.
| days | Ruxolitinib | Placebo |
|---|---|---|
| Overall Survival | 136.5 (95.0 to 196.0) | 129.5 (71.0 to 179.0) |
Progression-free survival was defined as the length of time between the date of randomization and the earlier of death or progressive disease (PD), whichever was earlier, as assessed by RECIST. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
| days | Ruxolitinib | Placebo |
|---|---|---|
| Progression-Free Survival (PFS) | 51.0 (42.0 to 84.0) | 46.0 (41.0 to 70.0) |
Objective response rate (ORR) was defined as the percentage of participants with either a confirmed complete response (CR) or partial response (PR) measured by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria during the treatment period. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Ruxolitinib | Placebo |
|---|---|---|
| Overall response | 7.8 | 1.6 |
| Complete response | 1.6 | 0.0 |
| Partial response | 6.3 | 1.6 |
Durable response was defined as subjects with a response of Partial response (PR) or better at 2 subsequent measurements that were at least 4 weeks apart.
| percentage of participants | Ruxolitinib | Placebo |
|---|---|---|
| Durable Response Rate | 7.8 | 0.0 |
A subject was considered a clinical benefit responder if he/she met at least 1 of the following criteria: 1. Subject showed improvement in at least one of the following parameters on successive scheduled observations without worsening in the others: pain intensity, analgesic use, or performance status 2. Subject was stable or improved on the pain intensity, analgesic use, and performance status and had a ≥ 7% increase in body weight maintained for 2 consecutive reporting periods that was not because of fluid accumulation.
| percentage of participants | Ruxolitinib | Placebo |
|---|---|---|
| Subjects with clinical benefit | 12.5 | 1.6 |
| Pain intensity - Improved | 10.9 | 1.6 |
| Analgesic use - Improved | 4.7 | 0.0 |
| Karnofsky performance status - Improved | 3.1 | 0.0 |
| Body weight - Improved | 3.1 | 0.0 |
Collected over From the start of the study (first dose for that subject) until the end of the Adverse Event (AE) period (30 days after the last dose) or death, whichever was earlier (up to 8 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib (Safety Run-In) | — | 5/9 (55.6%) | 9/9 (100%) |
| Ruxolitinib | — | 32/59 (54.2%) | 57/59 (96.6%) |
| Placebo | — | 35/60 (58.3%) | 59/60 (98.3%) |
| Event | Ruxolitinib (Safety Run-In) | Ruxolitinib | Placebo |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 2/9 | 2/59 | 5/60 |
| VomitingGastrointestinal disorders | 2/9 | 1/59 | 5/60 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 2/59 | 1/60 |
| NauseaGastrointestinal disorders | 1/9 | 2/59 | 5/60 |
| AstheniaGeneral disorders | 1/9 | 0/59 | 2/60 |
| SepsisInfections and infestations | 1/9 | 1/59 | 0/60 |
| Urinary tract infectionInfections and infestations | 1/9 | 0/59 | 1/60 |
| International normalized ratio increasedInvestigations | 1/9 | 0/59 | 1/60 |
| Failure to thriveMetabolism and nutrition disorders | 1/9 | 0/59 | 1/60 |
| Cerebrovascular accidentNervous system disorders | 1/9 | 0/59 | 1/60 |
| Event | Ruxolitinib (Safety Run-In) | Ruxolitinib | Placebo |
|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 7/9 | 30/59 | 12/60 |
| Abdominal painGastrointestinal disorders | 5/9 | 22/59 | 23/60 |
| VomitingGastrointestinal disorders | 5/9 | 14/59 | 21/60 |
| DehydrationMetabolism and nutrition disorders | 5/9 | 12/59 | 10/60 |
| FatigueGeneral disorders | 2/9 | 29/59 | 26/60 |
| NauseaGastrointestinal disorders | 4/9 | 21/59 | 27/60 |
| DiarrheaGastrointestinal disorders | 4/9 | 22/59 | 17/60 |
| StomatitisGastrointestinal disorders | 3/9 | 16/59 | 8/60 |
| Decreased appetiteMetabolism and nutrition disorders | 2/9 | 12/59 | 20/60 |
| Edema peripheralMetabolism and nutrition disorders | 3/9 | 7/59 | 6/60 |
| Age, Continuous(years) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| Mean | 61.6 ± 9.4 | 65.7 ± 9.3 | 66.3 ± 9.8 | 66.0 ± 9.5 |
| Sex: Female, Male(Participants) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 23 | 29 | 57 |
| Male | 4 | 41 | 34 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 5 | 6 |
| Not Hispanic or Latino | 9 | 62 | 58 | 129 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 9 | 6 | 18 |
| White | 5 | 54 | 54 | 113 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 2 | 3 |
| Height(cm) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| Mean | 171.67 ± 14.11 | 171.29 ± 11.93 | 168.27 ± 10.25 | 169.78 ± 11.18 |
| Weight(kg) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| Mean | 75.051 ± 17.317 | 75.014 ± 21.914 | 69.299 ± 16.260 | 72.156 ± 19.427 |
| Body mass index (BMI)(kg/m^2) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| Mean | 25.3 ± 4.209 | 25.354 ± 6.332 | 24.243 ± 4.237 | 24.789 ± 5.394 |
| Body surface area(m^2) | Ruxolitinib - Safety Run-In | Ruxolitinib | Placebo | Total |
|---|---|---|---|---|
| Mean | 1.869 ± 0.287 | 1.863 ± 0.297 | 1.791 ± 0.248 | 1.827 ± 0.275 |
The record gives a start of Jul 2011, a primary completion of Jun 2013 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 3 years 2 months after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib